Results 201 to 210 of about 54,075 (219)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2012
José Baselga, Serena Di Cosimo, Evandro de Azambuja   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2010
openaire   +1 more source

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Lancet, The, 2019
Louise Hiller, Anne-Laure Vallier, Karen McAdam   +2 more
exaly  

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Nature Reviews Clinical Oncology, 2009
Francisco J Esteva, Dihua Yu, Mien-Chie Hung   +2 more
exaly  

Trastuzumab/trastuzumab-deruxtecan

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2017
  +4 more sources

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

New England Journal of Medicine, 2012
Luca Gianni, Ian E Krop, José Baselga
exaly  

Trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly
  +4 more sources

Emtansine/pertuzumab/trastuzumab/trastuzumab

Reactions Weekly
openaire   +1 more source